PIK3CA and breast carcinoma: Another PI3Kα-targeted PROTAC, ZM-PI05, degrades both PI3Kα subunits (p110α and p85) and shows a lower IC50 than alpelisib in inhibiting proliferation of PIK3CA-mutant breast cancer cell lines (Zhang et al, 2024).